Organ-on-Chip Patents: Leaders, Trends & White Space 2026
A data-backed look at organ-on-chip and microphysiological system patents: who leads filings, how the field has grown since 2017, and where the IPC classes show under-claimed white space.
Filing growth = 2021 (203 records) → 2024 (150); 2024 is the last year we treat as complete. Top-5 share = the 5 largest assignees ÷ all 2,630 records in scope (CR5), not the ranked leaders only.
What the organ-on-chip patent record actually covers
Organ-on-chip and microphysiological system patents sit at the intersection of microfluidics, cell culture and material analysis. The search underlying this page captures 2,630 published records filed between 2015 and the 2026 data cut-off, spanning devices that model single organs through membrane-separated microfluidic layers as well as broader tissue-chip and lab-on-a-chip claims. Patent families are the more reliable unit here than raw document counts, since the same underlying invention often generates multiple continuations and jurisdictional filings.
The receiving-office spread shows the United States as the largest single jurisdiction, followed by WIPO PCT filings, EPO, China, Canada and Australia — a pattern consistent with a field still driven by academic and early-stage commercial actors filing broad international coverage before committing to national phase.
Filing trends and technology composition
Two views of the same 2,630-record dataset: how filing volume has moved year over year, and which IPC subclasses carry the claim density.
Filing trend: a 2018 peak, then a real but partial decline
Annual filings rose to a peak of 233 in 2018, then eased; the comparable complete-year window shows 203 filings in 2021 falling to 150 in 2024, a 26% drop over that three-year span. Counts for 2025 and 2026 are still filling in as publications catch up to filing dates, so they should not be read as a continued fall.
Publication lags filing by roughly 18 months, so 2025 onwards are still filling in. Growth rates on this page therefore end at 2024; running them to the last bar would understate the field.
Technology composition: bioreactor and analytical claims dominate
C12M (bioreactors & enzyme apparatus) and G01N (material analysis & testing) each appear in over 40% of the 2,630 records, with C12N (microorganisms & genetic engineering) and B01L (lab apparatus) also well represented. Because records can carry multiple IPC classes, these shares sum to more than 100%; MEMS-specific B81B and agrochemical A01N sit under 4% each, marking the narrower edges of the field.
Shares are the percentage of the 2,630 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Lab-on-a-Chip & Microfluidics: Organ On Chip Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about lab-on-a-chip & microfluidics: organ on chip patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe records shaping this field
Organ-on-a-chip and a fabrication method thereof (US12291700B2)
The disclosure describes an organ-on-a-chip built from three stacked layers, each with its own microfluidic channel for culturing organ cells, separated by two membranes. The structure lets a test drug's absorption into two different organ cell types be measured simultaneously, addressing a common limitation of single-organ chip designs.Filed by Inje University Industry-Academic Cooperation Foundation, published 2025-05-06.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6632655B1 | Manipulation of microparticles in microfluidic systems | 983 |
| 2 | US20040072278A1 | Microfluidic particle-analysis systems | 874 |
| 3 | US7294503B2 | Microfabricated crossflow devices and methods | 674 |
| 4 | WO2016040476A1 | A droplet-based method and apparatus for composite single-cell nucleic acid analysis | 429 |
| 5 | US20050053952A1 | Microfluidic nucleic acid analysis | 367 |
| 6 | WO2016138496A1 | Spatially addressable molecular barcoding | 333 |
| 7 | WO2016126871A2 | Sequencing of nucleic acids via barcoding in discrete entities | 332 |
| 8 | US20180030515A1 | Droplet-Based Method And Apparatus For Composite Single-Cell Nucleic Acid Analysis | 300 |
| 9 | US7312085B2 | Microfluidic particle-analysis systems | 293 |
| 10 | US20070026381A1 | Devices and methods for enrichment and alteration of cells and other particles | 280 |
Citation counts reflect influence within the searched corpus and favour older filings; they are not a measure of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data says before you file
Four figures worth checking before scoping freedom-to-operate work or a new filing in this space.
Leadership is real but not exclusionary
The leading assignee alone accounts for 192 records, and the top 5 combined hold 20.5% of all 2,630 records in scope. That leaves close to 80% of the field spread across a long tail — useful context if you're assessing how crowded a specific sub-claim actually is versus the field headline.
Volume has eased from its 2018 peak, not collapsed
Filings peaked at 233 in 2018 and the most recent complete comparison — 203 in 2021 down to 150 in 2024 — shows a real 26% decline. Given the roughly 18-month lag between filing and publication, 2025-2026 figures are still incomplete and should not be read as confirming further decline.
Bioreactor and analytical claims are the densest ground
C12M and G01N each appear in over 40% of the 2,630 records, meaning bioreactor architecture and material-analysis methods are the most heavily claimed territory. Filers targeting these classes should expect to design closely around existing structures rather than stake fresh ground.
Cross-institution filing is limited but concentrated
Only 10 co-assignee pairs appear across the dataset, and the strongest links are academic-institutional pairings rather than company-to-company alliances. This suggests most organ-on-chip IP is still built inside single institutions rather than through joint filing programmes.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to lab-on-a-chip & microfluidics: organ on chip patent landscape, with the prior art for and against each one.
Where to take this analysis
The dataset points to specific next questions depending on whether you're scoping a filing, a licence, or a competitive watch.
Map your own claim against the top classes
If your invention sits in C12M or G01N, run a tighter claim-by-claim comparison against the highest-cited records before drafting, since that ground is the most densely occupied in the dataset.
Explore claim mapping in EurekaTrack the long tail, not just the leader
With 80% of records held outside the top 5 assignees, a competitive watch limited to the largest filers will miss most of the activity. A broader monitoring set catches emerging entrants earlier.
Set up assignee monitoring in EurekaTreat 2025-2026 filing counts as provisional
Because publication lags filing by roughly 18 months, don't use the most recent two years to call a trend either way — revisit the filing curve again once those years have caught up.
Ask Eureka about filing lagCommon questions on organ-on-chip patents
Across the 2,630 records in scope, filings are led by a single assignee with 192 records, with the top 5 assignees combined holding 20.5% of all records. The tenth-ranked assignee holds 34 records, which shows the drop-off from leader to mid-pack is steep. Beyond the top 10, holdings spread across a long tail of academic and early-stage commercial filers, so no single entity controls the field outright.
Filings peaked in 2018 at 233 and the most recent complete comparison shows a real decline: 203 filings in 2021 down to 150 in 2024, a 26% drop. However, because patent publication typically lags filing by about 18 months, the lower counts shown for 2025 and 2026 in raw data are incomplete rather than evidence of a further fall. Treat any read of the last one to two years with that caveat in mind.
The two most common IPC subclasses are C12M, covering bioreactors and enzyme apparatus, and G01N, covering material analysis and testing, each appearing in over 40% of the 2,630 records. C12N (microorganisms and genetic engineering) and B01L (lab apparatus) are also heavily represented. Because a single patent can carry multiple IPC classes, these percentages overlap and sum to more than 100%, so they should be read as coverage share, not a breakdown of the whole field.
US12291700B2, filed by Inje University Industry-Academic Cooperation Foundation and published in 2025, claims a three-layer microfluidic chip with two membranes separating three channels, allowing simultaneous drug-absorption measurement in two different organ cell types. It is a useful recent example of multi-organ chip architecture rather than a single-organ device. Whether it blocks a new design depends on the specific channel and membrane arrangement claimed; a full claim chart against your own structure is the only reliable way to check, since citation counts alone don't indicate freedom-to-operate risk.
The narrowest classes in the dataset are B81B (MEMS microstructural devices) at 3.7% of records and A01N (biocides/agrochemicals applications) at 3.3%, both far below the 40%+ density of the bioreactor and analytical classes. This suggests device-level MEMS integration and agrochemical-testing applications of organ-on-chip platforms are comparatively under-claimed relative to the core bioreactor and analysis space. Co-assignee collaboration is also limited to only 10 identified pairs, hinting that joint-development filing strategies remain an open approach few competitors have used.
Research Lab-on-a-Chip & Microfluidics: Organ On Chip Patent Landscape in depth with Eureka
Go past this page: query the whole lab-on-a-chip & microfluidics: organ on chip patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.